A Unique SUMO-2-Interacting Motif within LANA Is Essential for KSHV Latency
Kaposi's sarcoma-associated herpesvirus (KSHV) stabilizes hypoxia-inducible factor α (HIF-1α) during latent infection, and HIF-1α reactivates lytic replication under hypoxic stress. However, the mechanism utilized by KSHV to block lytic reactivation with the accumulation of HIF-1α in latency remains unclear. Here, we report that LANA encoded by KSHV contains a unique SUMO-interacting motif (LANASIM) which is specific for interaction with SUMO-2 and facilitates LANA SUMOylation at lysine 1140. Proteomic and co-immunoprecipitation analysis further reveal that the SUMO-2 modified transcription repressor KAP1 is a critical factor recruited by LANASIM. Deletion of LANASIM led to functional loss of both LANA-mediated viral episome maintenance and lytic gene silencing. Moreover, hypoxia reduced KAP1 SUMOylation and resulted in dissociation of both KAP1 and Sin3A repressors from LANASIM-associated complex. Therefore, the LANASIM motif plays an essential role in KSHV latency and is a potential drug target against KSHV-associated cancers.
Published in the journal:
. PLoS Pathog 9(11): e32767. doi:10.1371/journal.ppat.1003750
Category:
Research Article
doi:
https://doi.org/10.1371/journal.ppat.1003750
Summary
Kaposi's sarcoma-associated herpesvirus (KSHV) stabilizes hypoxia-inducible factor α (HIF-1α) during latent infection, and HIF-1α reactivates lytic replication under hypoxic stress. However, the mechanism utilized by KSHV to block lytic reactivation with the accumulation of HIF-1α in latency remains unclear. Here, we report that LANA encoded by KSHV contains a unique SUMO-interacting motif (LANASIM) which is specific for interaction with SUMO-2 and facilitates LANA SUMOylation at lysine 1140. Proteomic and co-immunoprecipitation analysis further reveal that the SUMO-2 modified transcription repressor KAP1 is a critical factor recruited by LANASIM. Deletion of LANASIM led to functional loss of both LANA-mediated viral episome maintenance and lytic gene silencing. Moreover, hypoxia reduced KAP1 SUMOylation and resulted in dissociation of both KAP1 and Sin3A repressors from LANASIM-associated complex. Therefore, the LANASIM motif plays an essential role in KSHV latency and is a potential drug target against KSHV-associated cancers.
Introduction
Kaposi's sarcoma-associated herpesvirus (KSHV), or human herpesvirus 8 (HHV-8), is the etiological agent of Kaposi's sarcoma (KS), and is tightly associated with primary effusion lymphoma (PEL) and a subset of multicentric Castleman's disease (MCD) [1], [2]. KSHV is a large DNA tumor virus encoding more than 90 open reading frames (ORF). Like all herpesviruses, KSHV has two distinct phases of its life cycle: latency and lytic replication. During latent infection, only a few genes are expressed [3]. The latency-associated nuclear antigen (LANA) encoded by ORF73 is one of the dominant latent proteins with multiple functions. These include tethering the viral episome to the host chromatin, inhibiting tumor suppressors, regulating gene transcription and blocking apoptosis for establishment and maintenance of latent infection (reviewed in [4], [5], [6]. The replication and transcriptional activator (RTA) encoded by ORF50 is essential for initiation of viral lytic replication [7], [8], [9], [10]. RTA drives lytic replication via activation of a transcription cascade of KSHV genes expressed during the early stages of the viral life cycle [7], [9]. Studies of KSHV-induced cell transformation in vivo demonstrated that KSHV predominantly enters a latent state [11], [12]. However, clinical analysis of KS patient samples have shown that a fraction of infected cells can also enter into lytic replication producing infectious virions and expressing virus-encoded paracrine signaling factors [13]. This suggests that spontaneous reactivation from latency in the tumor microenvironment is also important for growth and dissemination of viral infected tumor cells.
Hypoxic stress is a common feature of the tumor microenvironment [14], [15], [16], which results from oxygen consumption by successive layers of tumor cells distal to blood vessels or temporary vessel closure [17]. The extent of tumor hypoxia is strongly associated with tumor development and malignant progression. To elucidate the effect of intratumoral hypoxia on KSHV-associated cancers, we and other groups have shown that hypoxic stress reactivates KSHV lytic replication in vitro [18], [19]. In hypoxia, the major latent antigen LANA together with the key hypoxia responder HIF-1α (the inducible subunit of the heterodimeric transcriptional factor HIF-1) binds to the hypoxia-responsive elements (HRE, 5′-RCGTGC-3′) within the RTA gene promoter inducing lytic replication [18]. Interestingly, under normoxic conditions, HIF-1α is aberrantly accumulated in both KSHV latently infected cells and KS patient tissues in a LANA-dependent manner [20], [21]. These results indicate that LANA plays a dual role in controlling HIF-1α transcriptional activity for KSHV latent and lytic replication. However, the mechanism utilized by LANA to exert this dual function in normoxia and hypoxia remains unclear.
Emerging studies indicate that post-translational modification of proteins by the small ubiquitin-like modifier (SUMO) plays an important role in epigenetic control of gene transcription, and in response to hypoxic stress [22], [23], [24], [25]. SUMO is covalently attached to a lysine residue of target proteins through an isopeptide bond by three enzymes: heterodimeric SUMO-activating enzyme E1 (Uba2-Aos1), SUMO-conjugating enzyme E2 (Ubc9), and the substrate recognition factors or E3 ligases (i.e. PIAS protein family) [26]. Different from ubiquitination, SUMO conjugation often requires a consensus sequence ΨKxE/D (Ψ, large hydrophobic residue; x, any amino acid) around the target lysine [27]. The consequence of SUMOylation leads to various facets of protein function, including regulation of gene transcription, cell cycle, DNA repair and subcellular localization. In mammalian cells, there are at least four isoforms of SUMO – SUMO-1, -2, -3 and -4. SUMO-1 is the major SUMO in human cells; SUMO-2 and SUMO-3 are highly similar and responds to different cellular stresses [28], [29]; and SUMO-4 is tissue specific and so far only found in the pancreas [30]. In addition to attaching covalently to substrates, SUMO can also non-covalently bind to other proteins through a consensus SUMO-interacting motif (SIM), which is identified as sequence h-h-x-S-x-S/T-a-a [31], V/I-x-V/I-V/I [32], or K-x3–5-I/V-I/L-I/L-x3-D/E/Q/N-D/E-D/E [33]. Thus, in regards to the biological functions of these modified substrates, the SUMOylated targets may depend on their ability to interact with other effectors containing SIM motifs.
In this study, we demonstrate that LANA contains a unique SUMO-interacting motif (LANASIM) specific for interaction with SUMO-2 and that LANA can also be SUMOylated on lysine 1140. Proteomic analysis further showed that LANASIM recruits a transcription inhibitory complex which includes two co-repressors KAP1 and Sin3A. Strikingly, we found that deletion of the LANASIM motif sufficiently abolishes its association with poly-SUMO2 modified KAP1, and loss of LANA's ability to support KSHV episome maintenance and gene silencing. Furthermore, hypoxia blocks poly-SUMO2 modified KAP1 and leads to dissociation of KAP1 and Sin3A from the LANASIM complex, as well as loss of LANA SUMOylation, which in turn transactivates viral gene expression for lytic replication. This describes the first mechanism by which a viral protein presents a specific SIM-motif platform to selectively recruit a cellular transcriptional complex for viral episome maintenance and gene silencing during latent infection.
Results
LANA contains a SIM motif which is specific for interaction with SUMO-2
To investigate whether LANA is involved with the SUMO-signaling pathway, we performed co-immunoprecipitation (co-IP) assays by co-expressing myc-tagged LANA with FLAG-tagged SUMO-1 or SUMO-2 under normoxic conditions. The results showed that LANA dramatically associated with the SUMO-2 not SUMO-1 modified substrate [(SUMO1/2)n-sb] with high molecular weight (>170 kDa) (Figure 1A, lanes 3 and 4). Interestingly, when hypoxic stress was induced by CoCl2 or 1% oxygen, the association of LANA with (SUMO2)n-sb was significantly reduced (Figure 1A, lanes 4, 6 and 8), while a moderate increase in the association of LANA with (SUMO1)n-sb was observed (Figure 1A, lanes 3, 5 and 7). In contrast, there was a reduced level of (SUMO2)n-sb [namely more “low” than “high” of (SUMO2)n-sb appearance] in whole cell lysates in hypoxia compared with normoxia (Figure 1A, compare lanes 4 with 6 and 8 in enlarged region), suggesting that the reduced association of LANA with (SUMO2)n-sb in response to hypoxia may be due to less SUMO-2 modification of target proteins.
To identify the domain required for LANA to interact with poly-SUMO-2, we performed similar co-IP assays by using different mutants of LANA. The results show that residues 233 to 340 at the amino terminus are critical for the strong interaction of LANA with the (SUMO2)n-sb (Figure 1B and supplementary Figure S1), and the central region which contains residues 329 to 925, a highly repetitive region provides minimal contribution to the interaction of LANA with (SUMO1)n-sb and (SUMO2)n-sb (Figure 1B and supplementary Figure S1C, upper panel). In contrast, as the position of (SUMO2)n-sb size did not change dramatically, even though the molecular weight of LANA truncated mutants (FL, NC, N3, N2 and N1) was varied from 65 kDa to 250 kDa. This indicates that the majority part of the detected (SUMO2)n-sb is not the SUMO2-modified LANA.
To further determine whether a cellular SUMO-interacting motif (SIM) -like sequence is located within the residues 233 to 340 of LANA, we aligned the LANA sequence with the three reported cellular SIM sequences [31], [32], [33]. The results identified two potential SIM-like motifs (SIM1 and SIM2) with partial homology to cellular SIM motifs both located within the residues 233 to 340 (Figure 1B and supplementary Table S1). To prove that these SIM motifs (LANASIM) are required for LANA to interact with the (SUMO2)n-sb, we generated a series of mutations within the SIM motif of LANA 1–340 (N3) by site directed mutagenesis and again performed similar co-IP assays with SUMO-2. Strikingly, the results show that deletion of the SIM1, SIM2, SIM1/2, or mutation of three residues within SIM2 motif (3IA or 3SA) resulted in a significant reduction in the interaction of LANA 1–340 with (SUMO2)n-sb (Figure 1C). Therefore, we speculated that the intact 3D structure of the SIM motif within the amino terminus of LANA is important for interaction with the (SUMO2)n-sb. To verify whether the LANASIM motif is specifically required for LANA to preferentially associate with (SUMO2)n-sb instead of (SUMO1)n-sb, we performed similar assays using full-length LANA or its NC truncated mutant with or without deletion of the SIM motifs. Indeed, deletion of the LANASIM motif completely abrogated the interaction of the NC truncated mutant of LANA with (SUMO2)n-sb while no detectable effect with (SUMO1)n-sb (supplementary Figure S1B, lanes 3 and 6), and also specifically reduced the interaction of full length LANA with (SUMO2)n-sb but not (SUMO1)n-sb (supplementary Figure S1C, compare lanes 4, 5 with 2, 3). In addition, the results from in vitro pull-down assays of His-SUMO-1 or SUMO-2 recombinant protein with radioactive labeled wild type LANA or its SIM-deleted mutant showed that LANA only bound to SUMO-2 not SUMO-1 and this interaction of LANA with SUMO-2 was dependent on the LANASIM motif (Figure 1D), further confirming that the LANASIM motifs are critical for LANA to strongly interact with (SUMO2)n-sb through SUMO-2.
To further confirm that LANASIM is required for LANA to interact with SUMO-2, we investigated the subcellular localization of LANA and SUMO-2 by using the wild type or SIM-deleted NC truncated mutant of LANA. Consistently, the results showed that SUMO-2 localizes predominantly to the outside compartment of chromosomal DNA when expressed alone (Figure 2A). However, we observed 64.8% co-localization of SUMO-2 with LANA on chromosomal DNA in the presence of wild type LANA (Figure 2B, upper panels). In contrast, only 0.5% SUMO-2 was co-localized with LANA on chromosomal DNA when the SIM motif of LANA was deleted (ΔSIM) (Figure 2B, lower panels). To further demonstrate this point, the sequential ChIP assays were performed in the presence of TR DNA. The results also showed that wild type not SIM-deleted mutant dramatically associated with SUMO-2 on DNA compartment (Figure 2C). This suggests that LANASIM is required for LANA to co-localize with SUMO-2 on chromosomal DNA. In consistence, the results from immunofluorescence analysis of endogenous LANA and SUMO-2 in PEL cells further supported the notion that hypoxia reduces co-localization of LANA with SUMO-2 (Figure 2D).
Poly-SUMO2 modified KAP1 is a key component of the LANASIM-mediated regulatory complex
To identify which proteins with SUMO-2 modification interact with the LANASIM motif, we first analyzed the 3D structure of LANA by Robetta prediction software (http://robetta.bakerlab.org/). Strikingly, we found that the region which contains residues 240 to 300 forms a separate domain with two sub-SIM (SIM1 and SIM2) motifs individually distributed on each side (Figure 3A). This potentially provides a “riding-horseback” like platform important for LANA interaction with poly-SUMO-2. In addition, we also noticed that the AD domain of the central region is located very close to the LANASIM motif (Figure 3A), which may explain why the deletion of the AD domain decreases the interaction of LANASIM with poly-SUMO-2. Based on this predicted 3D structure of the SIM domain, we generated a GST-SIM fusion protein by using the residues 240 to 300 region and performed GST pulled down assay with nuclear extracts from 293 cells expressing exogenous SUMO-2. The results from gel fractionation results showed that at least four unique bands (b1, b2, b3 and b4) were pulled down by the GST-SIM protein (Figure 3B, upper panel). Analysis of these bands by mass spectrometry identified five proteins: DNA-PKc, the transcriptional coactivators CBP and p300, and the corepressors Sin3A and KAP1, respectively (Figure 3B, lower panel). Interestingly, previous studies have suggested that these five proteins are responsive to hypoxic stress [34], [35], [36], [37]. In addition, except for DNA-PKc, the other four transcription factors were reported to undergo SUMO modification [38], [39], [40], [41]. To elucidate which proteins in this complex are critical for interaction with the LANASIM motif through poly-SUMO-2, we first performed similar GST pull-down assays by using GST fusion with the wild type (WT) or the SIM-deleted (ΔSIM) mutant of LANA N terminus 1–329, following western blot with specific antibodies for each of the five proteins. The results showed that deletion of the LANASIM motif results in a dramatically dissociation of KAP1 and Sin3A with the LANASIM-mediated complex (data not shown). To further verify if KAP1, Sin3A or both undergo SUMO-2 modification as LANASIM targets are impaired by hypoxia stress, HEK293 and BJAB cells individually transfected with FLAG-SUMO-2 or vector were treated with or without hypoxia and subjected to denature IP of KAP1 and Sin3A. The results showed that KAP1 but not Sin3A was dramatically modified by SUMO-2 (1, 2, 3 and 4 copies of SUMO-2 according to 19 kDa molecular weight of SUMO-2) in the presence of FLAG-SUMO-2. Furthermore, this modification was blocked by hypoxia (Figure 3C, compare lanes 2 with 4, similar results were observed in BJAB cells). Intriguingly, although the denatured form of SUMOylated KAP1 (de-suKAP1) was not pulled down by the SIM domain of LANA fusion with GST in vitro (data not shown), the native co-immunoprecipitation assays showed that the LANASIM motif within full length LANA or its NC truncated mutant had a higher affinity with 2×SUMO-2 modified KAP1 than 1×SUMO-2 modified one (Figure 3D, lanes 1 and 3), and deletion of the LANASIM motif dramatically reduces or completely abrogates the interaction of LANA with 1 or 2× SUMO-2 modified KAP1 (Figure 3D, compare lanes 1 and 2 with 3 and 4). Unexpectedly, deletion of SIM motif in both full length LANA and its NC truncated mutant led to appearance of a degraded band (∼95 kDa) (Figure 3D, lanes 2 and 4 indicated by asterisk). The result of less association of LANA with native Sin3A once the SIM motif was deleted (Figure 3D, middle panel, lanes 2 and 4), further supports the notion that the poly-SUMO2 modified chain of KAP1 is the critical one targeted by the LANASIM motif. In addition, the results of in vitro binding assays showed no direct interaction of His-KAP1 with in vitro translated proteins of full length LANA and its different truncated mutants (Figure 3E), suggesting that LANA predominantly interacts with poly-SUMO2 modified KAP1 through the LANASIM motif.
To further confirm that LANA does bind with the SUMO-2 modified KAP1, the wild type KAP1 and its mutant 6KR (all 6 putative SUMOylated lysines are mutated to arginine) with FLAG tag were individually used to perform co-IP with myc-tagged LANA in the presence of HA-SUMO-1, HA-SUMO-2 or vector alone. The results showed that as observed with endogenous KAP1 and SUMOylation, LANA strongly associated with 1 or 2×SUMO-2 modified KAP1 with greater affinity for the 2×SUMO2-KAP1, although there was more 1× SUMO-2 modified KAP1 seen in the whole cell lysate (Figure 4A). Furthermore, the results of LANA association with 1 or 2×SUMO-2 modified KAP1 with the lysines mutated indicated that LANASIM binds preferentially with poly-SUMO2 modified KAP1 and that these lysines contributed to KAP1 SUMOylation to various degrees with a complete loss of association when all 6 lysines were mutated (Figure 4B). In PEL cells with hypoxia, less association of SUMO2-modified and native KAP1 with endogenous LANA than that in normoxia (Figure 4C), further demonstrated that the association of LANA with KAP1 is sensitive to hypoxic stress.
The LANASIM motif is important for SUMO-2 modification of LANA
To determine whether the LANASIM motif of LANA contributes to its SUMO modification, we performed native and denatured (which removes non-covalent binding but retains covalent binding of SUMO modification), co-IP assays by using full length LANA or its LANASIM-deleted mutant (LANAΔSIM) coexpressed with exogenous SUMO-1 or SUMO-2. Ubc9 was used as a positive control in this assay. The results showed that LANA can be modified by both SUMO-1 and SUMO-2 (supplementary Figure S2, upper panels). Importantly, the signals indicating that LANA was SUMO-2 modified were greater than that seen for SUMO-1 (supplementary Figure S2, upper panel, lanes 5 and 6). Consistent with our findings that the LANASIM motif associates with SUMO-2 but not SUMO-1, and the LANASIM motif deletion resulted in a remarkable reduction of SUMO-2 modification of LANA (supplementary Figure S2, compare lanes 6 with 8). In contrast, the levels of SUMO1-modified LANA were relatively unchanged in the ΔSIM mutant compared to WT LANA (supplementary Figure S2, compare lanes 5 with 7).
As the LANASIM-associated poly-SUMO2 modified KAP1 is highly sensitive to hypoxic stress, we wanted to know if SUMO-2 modification of LANA is also impaired by hypoxia. We monitored the SUMO-2 modified levels of endogenous LANA by in vivo SUMOylation assays in PEL cells under normoxic and hypoxic conditions. The KSHV negative (no LANA) BJAB cell line was used as a negative control. The results showed that the levels of both SUMO-2 modified LANA (suLANA) and native LANA associated with SUMO-2 in BC3 cells are also dramatically reduced under hypoxic conditions (supplementary Figure S3). This corroborated the above data that the LANASIM motif does contribute to SUMO-2 modification of LANA due to dissociation from hypoxia-sensitive SUMOylated KAP1.
To determine which residues of LANA targeted for SUMOylation, we tested the SUMOylated pattern of different amino or carboxyl truncated forms of LANA (to avoid the problem of resolution of the SUMO-modified bands linked to full length LANA) in the presence of SUMO-1 or SUMO-2 by in vivo SUMOylation assays. The results showed that when coexpressed with SUMO-1 or SUMO-2, only the central region deleted (NC) and carboxyl terminus mutants of LANA but not its amino terminus mutant appear to have SUMO-1 or SUMO-2 modified forms of LANA (with slower migration compared to unmodified LANA) (data not shown). To identify which specific residues are SUMO modified, we analyzed the carboxyl terminal sequence of LANA according to the SUMOylated consensus sequence ΨKxE/D [27], and identified two lysine residues 1081 and 1140 which are most potentially targeted for SUMOylation (supplementary Figure S4, right panel). Follow-up SUMOylation assays in cells indicated that lysine 1140 of LANA is the key residue for both SUMO-1 and SUMO-2 modification (supplementary Figure S4, left panel).
In view of the fact that the LANASIM motif contributes to SUMOylation of LANA, to further verify if the LANASIM-associated complex (including KAP1) acts as a bridge for the amino terminus of LANA to interact with its carboxyl terminus, and in turn enhances SUMO modification of carboxyl terminus of LANA, we performed co-IP assays by expressing FLAG-tagged C terminus of LANA (LANA-C) with myc-tagged amino terminus (WT or ΔSIM) of LANA (LANA-N) in 293 cells. The results showed that the association of the amino terminus with the carboxyl terminus of LANA is dependent on the presence of SIM motif to a large extent (supplementary Figure S5A, lanes 2 and 3). In addition, co-expression of the amino with the carboxyl terminus of LANA dramatically enhances the SUMOylation at its carboxyl terminus (supplementary Figure S5B, lanes 1 and 2). Furthermore, the levels of the amino terminus-induced SUMOylation of the carboxyl terminus were significantly decreased when LANASIM-associated KAP1 was knocked down (supplementary Figure S5B, compare lanes 2 with 4). This further supports the notion that the LANASIM motif and KAP1 play a role in SUMOylation of LANA.
The LANASIM motif is essential for KSHV episome maintenance, silencing RTA expression and blocking lytic replication
Since LANA plays a critical role on maintenance of viral episome during latency, we wanted to know if the LANASIM deletion impairs the ability of LANA binding with the TR and the persistence of the viral episome during cell passage. To this end, we performed chromatin immunoprecipitation assays by using wild type (WT) LANA or a series of its mutants (ΔSIM, ΔAD, ΔAD, SIM and C) co-expressed with the TR-Puromycin plasmid in 293 cells for 48 hours. The results showed that there were no significant difference between wild type LANA and other mutants (Figure 5A, upper panels). To further determine if the persistence of LANA-binding TR was affected, the transfected cells of LANA and TR-Puromycin were subsequently subjected to colony formation assay where cells with TR plasmid were selected with Puromycin for 2 weeks (a greater number of colonies would indicate higher efficiency of the TR persistence). The results showed that both wild type (WT) LANA and its NC truncated mutant (ΔAD) presented the highest efficiency of TR maintenance, while both LANASIM-deleted mutants ΔSIM and ΔAD, SIM led to a dramatic loss of TR colonies (Figure 5A, lower panels). In contrast, due to the absence of the amino terminus of LANA for tethering to host chromosomal DNA [42], there was little or no TR colony formation seen in the carboxyl terminal truncated mutants (C) which were similar to vector alone (Figure 5A, lower panel). These results indicate that the LANASIM motif is an important contributor to LANA's role in maintenance of the KSHV episome.
To answer if the LANASIM motif also contributes to inhibition of lytic replication, we transiently transfected LANASIM -deficient mutants of LANA as a dominant negative into 293 cells stably carrying the complete KSHV-Bac36 (viral genome), and then monitored for intracellular viral episomal DNA by quantitative PCR analysis. Results with wild type LANA, NC truncated mutant ΔAD or vector alone as control dramatically reduced virion DNA production. However, we also showed that both the LANASIM-deleted mutants ΔSIM and ΔAD, SIM dramatically enhanced viral episome replication (Figure 5B). This strongly suggested that in addition to maintenance of the viral episome, the LANASIM-associated complex including KAP1 and Sin3A are also important for blocking lytic replication. To determine whether this LANASIM -dependent inhibition of lytic replication is due to silencing RTA (the key activator of the KSHV lytic life cycle) expression, the RTA promoter was subjected to luciferase reporter assays in the presence of wild type LANA, its mutants with or without LANASIM deletion (ΔSIM, ΔAD, and ΔAD,SIM) or vector alone. The results showed that the LANASIM-deletion alone (ΔSIM) recovered about 60% of the inhibition of wild type LANA whereas the ΔAD mutants had negligible effect (Figure 5C, left panel). However, the ΔAD,SIM mutant led to an almost complete reversal of the inhibitory activities (Figure 5C, left panel). In contrast, hypoxic stress efficiently reversed the inhibitory function of LANA resulting in transactivation of the RTA promoter regardless of whether the wild type LANA or the NC truncated mutants with or without LANASIM deletion (ΔAD, ΔAD,SIM) were used in the assay (Figure 5C, right panel). This further supports the notion that the LANASIM-mediated complex (including KAP1) is involved in the inhibitory function of LANA in RTA expression and is sensitive to hypoxia. To further confirm that LANASIM-mediated KAP1 and Sin3A are indeed required for LANA to repress the RTA promoter through the LANASIM motif, we performed RTA promoter reporter assays in the presence or absence of LANA in both BJAB and 293 cell lines with Lentivirus-mediated constitutive knockdown of KAP1 or Sin3A or nonspecific control. Consistent with our findings, the results showed that knockdown of KAP1 or Sin3A efficiently blocked the inhibitory function of LANA on the RTA promoter in normoxia (Figure 5D). This is consistent with our observation that the dominant negative LANASIM-deleted mutant does in fact enhance KSHV virion production (Figure 5B).
To determine whether the hypoxia-induced functional switch of LANA is due to the dissociation of the LANASIM-associated proteins (like KAP1 and Sin3A) from the regulatory complex LANA-HIF-1α particularly on the HIF-1α-DNA binding sites, we performed a biotin-labeled DNA oligo pull-down assay in vitro by incubating the nuclear extract with wild type or a mutant of the HIF-binding site-(mut) HRE DNA oligo. The specific proteins bound to HRE were pulled-down by Strepavidin agarose beads and were subjected to western blot analysis. The results showed that in normoxia the LANASIM-associated proteins KAP1 and Sin3A in the regulatory complex of LANA and HIF-1α bound to HRE (Figure 6A). However, in hypoxia, KAP1 and Sin3A as well as SUMO-2 (where the SUMO-2 position corresponds to the pattern of poly-SUMO2 modified KAP1 as calculated by molecular weight) were dramatically released from the LANA-HIF-1α/HRE complex (Figure 6A, right panels). Notably, we observed that a modified form (potential SUMO-2 modification based on the pattern of SUMO2 modified LANA) of LANA was also dissociated from the LANA-HIF-1α/HRE complex while interestingly HIF-1α appears with an additional modified slower migrating band (Figure 6A, right panels). To further determine if SUMOylation is important for DNA binding of the LANASIM-mediated complex, the ChIP assays of HRE region within the ORF50 promoter were carried out in BC3 cells with or without transiently Ubc9 knockdown. The results showed that inhibition of Ubc9-mediated SUMOylation dramatically reduced both KAP1 and Sin3A association with LANA-HIF-1α complex at the HRE DNA (Figure 6B). Taken together, this data above strongly support our hypothesis that KAP1 and Sin3A particularly SUMO-2 modified forms are indeed sensitive to hypoxic stress and are recruited by the LANASIM motif during KSHV latent infection to silence the RTA promoter under normoxic conditions.
Discussion
Despite the fact that latent infection is the dominant form of KSHV infection which leads to transformation of the host cell, reactivation from latency is also important for the growth and dissemination of viral associated tumor cells [13]. In addition to chemical triggers like phorbol esters and sodium butyrate, reactivation from KSHV latency can also be initiated by various physiological and environmental factors including hypoxia [43]. These agents are thought to directly or indirectly target the transcriptional activation of the promoter which drives the KSHV RTA (ORF50) immediate-early gene. Our previous studies showed that LANA encoded by KSHV cooperates with HIF-1α bound to the HREs of the RTA promoter to induce lytic replication under hypoxic conditions [18]. Interestingly, we also found that LANA stabilizes HIF-1α in normoxia by blocking the negative regulators VHL and p53 and inducing nuclear accumulation [20], [44]. To investigate how LANA switches from its inhibitory function to transcription activation at the RTA promoter, we now report that LANA has a unique SUMO2-interacting motif (LANASIM) and that this LANASIM motif specifically recruits a transcriptional inhibitory complex containing KAP1 and Sin3A for maintenance of the KSHV episome, as well as silencing of lytic gene (i.e. RTA) expression under normoxic condition. Of this complex, the poly-SUMO2 modified KAP1 is a critical factor targeted by the LANASIM motif. In hypoxia (i.e. 1% O2 in this study), loss of SUMOylation of KAP1 leads to the LANASIM-associated complex particularly KAP1 and Sin3A dissociation from the LANA-HIF-1α/HRE complex, as well as deSUMOylation of LANA itself, which open the active form of LANA-HIF-1α, and in turn induces lytic gene expression and reactivates lytic replication in response to hypoxic stress (Figure 6C). Interestingly, despite the fact that much dramatically dissociation of KAP1 and Sin3A from HIF-1α/HRE complex in the less SUMOylation status upon hypoxic stress, we did also observe that less native LANA association with HIF-1α/HRE complex to some extent in hypoxia when compared with that in normoxia, which could be due to the less stability of LANA without SUMO modification in hypoxia.
The modification of proteins by SUMO conjugation has been demonstrated as a reversible process important for regulating the function of many target proteins [45], [46]. The consequences of SUMO modification are not completely understood but have been shown to control various facets of protein function, including gene transcription, cell cycle, DNA repairs and protein localization [45], [46]. The most recent discovery of SUMO-interacting motif leads further interpretation to the roles that SUMO modification can play on protein-protein interaction, conformational changes and subcellular localization [31], [32], [33]. In this study, we discovered that LANA has a unique SUMO-2 interacting motif (LANASIM) containing two SIM motifs with partial homology to cellular SIM motifs. Furthermore, this LANASIM motif specifically associated with poly-SUMO-2 instead of poly-SUMO-1. The finding of poly-SUMO2 (2×SUMO-2) modified KAP1 associated with the LANASIM motif indicates that this interaction requires the intact 3D structure of the LANASIM motif. Notably, since SUMO-2 signaling is only activated due to extracellular stress, LANA may possess a unique SUMO-2 instead of SUMO-1 interacting motif to usurp the host SUMOylation pathway by mimicking stress signaling (This could be the reason why LANASIM greatly associates with certain target proteins instead of others with SUMO-2 modification), thus creating a cellular environment favorable for viral infection. Other instances including cytomegalovirus IE2 [47], human papillomavirus E2 [48], Epstein-Barr virus BZLF1 [49], and KSHV K-bZIP [50], [51], further support this notion. Our findings which showed that the AD domain of LANA's central region partially contributes to the LANASIM-associated protein-protein interaction, which subsequently enhances SUMO modification of LANA, supports previous discoveries that acidic residues located downstream from the core SUMO modification sites will enhance the efficiency of SUMOylation of target proteins [52]. In addition, we did not find a similar LANASIM-motif sequence within EBNA1 (the LANA homologous antigen encoded by Epstein-Barr virus), or ORF73 encoded by HVS C488, A11 or MHV68. In contrast, distinct from recent report indicating that a SIM motif is located at carboxyl terminus of LANA and required for SUMOylation of histone H2B [53], the hypoxia-based LANASIM discovered at amino terminus of LANA in our study could mainly target high-molecular-weight proteins (i.e. KAP1) instead of low-molecular weight ones (i.e. H2B). The fact that the LANASIM motif is required for interaction between amino and carboxyl terminal domains of LANA, further suggests that the LANASIM motif could serve as an adaptor for both intra-molecular and inter-molecular interactions of LANA as well as with other SUMO target proteins.
The LANASIM motif recruits a specific transcriptional regulatory complex which includes corepressors, coactivators, and DNA binding proteins. KAP1 (also known as TIF1β or TRIM28) was identified as a key component of the complex. It is well known that KAP1 is a universal corepressor protein from the Kruppel associated box (KRAB)-domain containing zinc finger proteins, the largest family of transcriptional silencers in the human genome [54], [55]. KAP1 itself cannot bind DNA directly and recruits or coordinates the assembly of several chromatin-remodeling proteins including the histone deacetylase complex (NCoR1) [56], and the heterochromatin protein 1 (HP1) family member [57]. Emerging evidence suggests that post-translational modifications, such as SUMOylation and phosphorylation can affect the ability of KAP1 to condense or relax chromatin [41], [58]. SUMOylation at Lys554, Lys779 and Lys804 of KAP1 generates a binding platform for SETDB and HADC1 to condense chromatin [58] (This may explain why there was a lower percentage of KAP1 matched peptide than other proteins like Sin3A in MALDI-TOF-MS assay). In response to hypoxia, KAP1 was previously shown to be phosphorylated in an ATM-dependent manner on Ser824, and phosphorylated KAP1 spreads rapidly throughout the chromatin [59]. In this study, the result of less SUMOylation of KAP1 in hypoxia provides further evidence that SUMOylation of KAP1 is hypoxia-sensitive and is linked to chromosome condensation and gene silencing. Therefore, knocking down KAP1 will lead to constitutive relaxation of cellular and viral chromatin for gene transcription and expression [60]. Taken together, these results provide a better understanding of the mechanism by which hypoxia drives the dissociation of KAP1 from LANA containing complexes for transactivation of target gene promoters.
Another key transcriptional co-repressor identified associated with the LANASIM motif was Sin3A. Like KAP1, Sin3A also functions as a co-repressor by recruiting HDAC1 for gene silencing [61]. Although Sin3A is shown as a substrate of TOPRS SUMO E3 ligase [40], it was difficult to detect the SUMOylated form of Sin3A directly associated with the LANASIM motif. However, the evidence of Sin3A knockdown results in dramatic attenuation of the enhancement of the transcriptional activity at the RTA promoter, indicating that Sin3A is also a key component in the LANASIM-associated complex. In addition, both transcriptional co-activators p300 and CREB-binding protein (CBP) were also pulled down by the LANASIM domain. However, albeit that the LANASIM deletion did not significantly impair their association with LANA, which minimizes a critical role for these co-activators in the LANASIM-associated silencing complex, their contributions cannot be completely ruled out. The aim of LANA targeting p300 and CBP is likely to take advantage of the amount of p300 and CBP in order to compete with other DNA bound transcriptional factors and so is important for balancing the repression and activation at these major lytic promoters.
Although a recent report showed that the lytic protein vPK blocks the SUMOylation of KAP1[62], the fact that deSUMOylation of KAP1 in hypoxia not only occurs in KSHV positive cells but also negative cells, argues against the possibility that hypoxia may up-regulate other viral antigens which in turn lead to the loss of SUMOylation of KAP1. In addition, the evidence that both KAP1 and Sin3A is released from the LANA-HIFα complex binding to the HRE elements during hypoxic stress provides additional questions for further investigation: 1) Is the deSUMOylation enzyme SENP up-regulated by hypoxia stress, and does deSUMOylation of KAP1/Sin3A by SENP lead to loss of KAP1/Sin3A binding with LANA in the silencing complex; 2) Does native or modified HIF-1α bind to LANA and block the access of KAP1 and Sin3A to the LANASIM motif?
In summary, our study provides new mechanistic insights into the programmed regulation of the KSHV genome during latent and lytic replication controlled by the major latent antigen LANA for gene silencing or activation based on a specific LANASIM-associated complex. Particularly, the discovery that the LANASIM-associated complex is highly sensitive to hypoxia (a physiologically relevant environmental condition) and so provides a potential therapeutic target against KSHV-associated cancers.
Materials and Methods
DNA constructs and antibodies
Plasmids encoding full length LANA with myc tag and its truncation mutants NC (1–329∧925–1162), N1 (1–435), N2 (1–233), and N3 (1–340) were previously described [20]. GFP-C1(930–1162)-myc and C(842–1162)-FLAG of LANA were obtained by ligating KpnI/EcoRV PCR fragments into pA3M-GFP and pA3F vector, respectively. GST-SIM(240–300), GST-LN1–329,and GST-LN1–329ΔSIM were generated by ligating KpnI/EcoRI PCR fragments into the derivative of pGEX-2TK (Introduced a KpnI restriction enzyme site in open reading frame of GST). HA-Ubc9 was generated by ligating BamHI/EcoRI PCR fragments into the plasmid of pcDNA3-HA. Plasmids pRta-Luc, HA-SUMO-1/2, FLAG-SUMO-1/2, GFP-SUMO-1/2 were described as previously [18], [22]. His-SUMO-1 and His-SUMO-2 were individually generated by ligating BamHI/HindIII and BamHI/EcoRI PCR fragments into the plasmid of pET-15b. His-KAP1 was generated by NdeI/BglII PCR fragment into pET-28a vector with NdeI/BamHI digestion. Briefly, mutants of full length LANA-myc (ΔSIM), NC-myc (ΔSIM), LANA-N3-myc (ΔSIM1, ΔSIM2, ΔSIM, 3IA and 3SA), GFP-LANA-C1-myc (K1081R), and -(K1140R), FLAG-KAP1 with Lysine 779 (K779), Lysine 804 (K804), Lysine 779,804 (K779,804), Lysine 554,804 (K554,804) or Lysine 554, 804,779 (K554,804,779)only were generated by PCR site-directed mutagenesis. All constructs were confirmed by direct DNA sequencing. Wild type FLAG-KAP1 and its 6KR mutant were kindly provided by Dr. Frank J Rauscher III from the Wistar Institute, Philadelphia [58].The SUMO-1 (Y299), DNA-PKcs (18-2), KAP1 (20C1) and β-actin (#8226) antibodies were from Abcam. HIF-1α antibodies were from BD transduction laboratory. Sin3A (AK-11), SUMO-2/3 (FL-103), GFP (F56-BA1), p300(C-20), and CBP(A-22) were purchased from Santa Cruz Biotech. Inc. GAPDH (G8140-01) antibodies were from US Biological Inc.. Mouse monoclonal antibodies against LANA (LANA1, or LNA1 rat mAb from Advanced Biotech Inc.), hemagglutinin (12CA5), FLAG (M2), and myc (9E10) were used as described previously [20].
Cell culture, transfection and hypoxic incubation
KSHV-negative (BJAB) and positive (BC3, BCBL1) B lymphoma cells were cultured in RPMI supplement with 7% FBS (Hyclone). HEK293 cells and 293/Bac36 stable cell line (established by 293 cells transfected with wild type KSHV BACmid [Bac36] and selected by 150 ng/ml Hygromycin B [Sigma]) were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 5% FBS (Hyclone). Transfections were performed by electroporation with a Bio-Rad Gene Pulser in 0.4 cm-gap cuvettes at 220 Volts and 975 microfarads. Cells were grown in a humidified atmosphere at 37°C at gas tensions of 21% O2/5% CO2 for normoxic incubation and 1% O2 (or 21% O2 with 100 µM CoCl2)/5% CO2 for hypoxic incubation as described previously [22].
Immunoprecipitation and immunoblotting
Immunoprecipitation (IP) and immuno-blotting assays were performed as described previously [44]. For denatured IP, cells were boiled 10 min in 2% SDS-containing Tris-buffered saline (TBS), followed by sonication and 18-fold dilution with TBS containing 1% Triton X-100. The cell lysates were immunoprecipitated with specific antibody as indicated, followed by immunoblotting with specific antibodies. The membrane was stripped using stripping buffer (200 mM Glycine, 1% SDS, pH 2.5) for re-immunoblotting.
Immunofluorescence
Immunofluorescence assays were performed as previously described [18]. Briefly, cells were washed with ice -cold phosphate-buffered saline (PBS) and incubated on polylysine treated coverslips for 20 min (HEK293 cells were directly grow on sterile coverslips and washed once with PBS) and then fixed in 3% paraformaldehyde for 20 min at room temperature. After fixation, cells were washed three times in PBS and permeabilized in PBS containing 0.2% fish skin gelatin (G-7765, Sigma), 0.2% Triton X-100 for 5 min, and then followed the primary and secondary antibodies staining. DNA was counterstained with DAPI (4′,6′-diamidino-2-phenylindole), and Coverslips were mounted with p-phenylenediamine. Cells were visualized with a Fluoview FV300 (Olympus Inc., Melville, NY) confocal microscope.
Protein expression, and in vitro pull-down assays
Overnight starter cultures (50 ml) of BL21 (DE3) transformed with plasmid expressing GST, GST-fused protein, or His-fused protein were incubated into 500 ml of Luria Broth (LB) culture medium with specific antibiotic and grown at 30°C to an optical density of about 0.6 at 600 nm. After isopropylthiogalactopyranoside (IPTG) induction (1 mM, 4 hrs at 30°C), the bacteria were collected and sonicated in lysis buffer containing 20 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.5% NP40, 1 mM EDTA, 1 M DTT, 5% Sarkosyl and the protease inhibitor cocktail for use with mammalian cell extracts or in vitro translated and radiolabeled proteins. His-SUMO-1, His-SUMO-2 and His-KAP1 proteins were purified by Ni2+-NTA Agarose chromatography (Qiagen), and GST, GST-SIM, GST-LANA1–329, or GST-LANA1–329ΔSIM was purified by Glutathione Sepharose chromatography (Amersham Biosciences). For pull-down assay, 35S-methionine-labeled in vitro-translated proteins or cell nuclear extracts were individually incubated with the relevant His or GST-fusion proteins loaded on beads for 3 hrs at 4°C in NETN binding buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 µm ZnCl2, 10% glycerol, freshly supplemented with 0.1 mM Dithiothreitol (DTT) and protease inhibitor). After washing, bound proteins were eluted with SDS sample buffer and analyzed by gel electrophoresis followed by direct autoradiography and scan by PhosphoImager (Amersham Biosciences Inc.) or immunoblotting with specific antibodies.
Protein identification by mass spectrometry
Gel slices were excised and proteins subjected to tryptic digest followed by peptide identification by lc-ms/ms using a hybrid high resolution quadrupole time-of-flight electrospray mass spectrometer. Results were analyzed suing MASCOT database search tool (Matrix Science).
Stable RNAi-expressing cell line production and transduction
The KAP1 shRNA sequence (5′-GCATGAACCCCTTGTGCTG-3′), Sin3A shRNA sequence (5′- CAACTGCTGA GAAGGTTGATTCTGT-3′), and the control sequence (5′-TGCGTTGCTAGTACCAAC-3′, non-targeting sequence), were individually inserted into pGIPz vector according to the manufacturer's instructions (Clonetech). The pGIPz containing shRNA sequence was cotransfected with Lentivrus package expressing plasmids (Rev, VSVG and gp) into Core T cells by Calcium phosphate method to generate virus. The packaged viruses were used to individually transduce target cells (BC3, BCBL1, or HEK293) and selection by 1–4 µg/ml puromycin. The RNA interfering efficiency was assessed by western blot analysis with specific antibodies.
Chromatin immunoprecipitation
The chromatin immunoprecipitation (ChIP) experiments were done essentially as previously described with some modifications [63], [64]. Cells (3×108) were cross-linked with 1.1% (v/v) formaldehyde, 100 mM NaCl, 0.5 mM EGTA, and 50 mM Tris-HCl (pH 8.0) in growth medium at 37°C for 10 min, then at 4°C for 50 min. Formaldehyde was quenched by adding 0.05 vol 2.5 M glycine. Fixed cells were washed with PBS, incubated for 15 min in 15 ml of 10 mM Tris-HCl (pH 8.0), 10 mM EDTA, 0.5 mM EGTA, and 0.25% (v/v) Triton X-100, followed by 15 min in 15 ml of 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, and 200 mM NaCl, and finally sonicated in 1 ml of 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1% (w/v) SDS plus 1 mM PMSF, 1 µg/ml aprotonin, leupettin, and pestatin) to an average fragment size of 300–500 bp. Solubilized chromatin extracts were clarified by centrifugation at 12,000 g, and diluted to 6 OD260 U/ml in IP buffer [140 mM NaCl, 1% (w/v) Triton X-100, 0.1% (w/v) sodium deoxycholate, 1 mM PMSF, 100 µg/ml salmon sperm DNA, and 100 µg/ml BSA]; pre-incubated for 1 h at 4°C with 10 µl/ml 50% (v/v) protein A-Agarose (Invitrogen Life Technologies) with normal mouse/rabbit sera; reconstituted in PBS, and washed several times in IP buffer. Aliquots (600 µl) were incubated with 20 µg of each specific antibody for overnight at 4°C. Immune complexes were separated into bound and unbound complexes with protein A-agarose and cross-links were reversed by treatment at 65°C overnight. After treatment with RNase A and proteinase K, samples were extracted once with phenol/chloroform, and the DNA was precipitated with 2 volumes of ethanol plus 10 µg of glycogen as carrier (Roche). Precipitated DNA was pelleted, washed once with 70% ethanol, dried, and resuspended in 100 µl of water. The DNA was analyzed by PCR using specific primer. For sequential ChIP, a second immunoprecipitation was performed using chromatin samples eluted from the agarose beads of the first ChIP by 10 mM DTT in 37°C for 30 min twice. Relative enrichment of DNA binding was shown as a percentage of input.
Preparation of nuclear extracts
Cells were resuspended in 4 times the volume of the pellet in NE buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2 with protease inhibitors) after cold PBS wash, and incubated on ice for 1 hour, and then transfer to precold douncer and homogenize with 25 strokes. Homogenized samples were transferred to eppendorf tubes and span at 2000 rpm for 5 mins at 4°C. Aspirate supernatant and resuspend the pellet in 2 times the volume of NE Buffer B (20 mM HEPES pH 7.9, 10% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA with protease inhibitors). Incubate on ice for 30 mins and Centrifuge at 13000 rpm for 20 mins at 4°C. The supernatants were transferred to fresh eppendorf tube and add an equal volume of NE Buffer C (20 mM HEPES pH 7.9, 30% glycerol, 1.5 mM MgCl2, 0.2 mM EDTA with protease inhibitors). Aliquot and snap freeze samples at −80°C before use.
In vitro DNA binding affinity assay of HIF-1α complex
Two complementary 5′-biotinylated oligonucleotides with or without HIF-1α-binding site (wt: 5′-GGATTCCAAACGTGCCCAGCG GT-3′; mut: 5′-GGATTCCAATTAATCCCAGCGGT-3′ underline indicates HIF-1α-binding site) were annealed to be double strands DNA and coupled to streptavidin-conjugated agarose beads. Per sample, 3 µg of biotinylated oligonucleotide was incubated with 40 ul of 50% streptavidin–conjugated agarose bead slurry (Thermo scientific) in a total volume of 100 ul of a lysis buffer comprised of 50 mM Tris-HCl, pH 8.0, 15 mM NaCl, 0.1 mM EDTA, 10% glycerol, 10 mM N-ethylmaleimide (NEM), 1 mM PMSF, 1 mM DTT, 1 µg/ml aprotonin, 1 µg/ml leupeptin, 1 µg/ml pepstatin for 2 h at 4C. Cell nuclear extracts (400 µg) was incubated with 40 µl of DNA-coupled Agarose beads in lysis buffer at a total volume of 500 µl for 3 hr at 4C. The precipitated complexes were washed three times with lysis buffer. Purified DNA-binding proteins were boiled in SDS sample buffer and analyzed by SDS-PAGE and immunoblotting. Equally 5% input amount of biotinylated DNA oligonucleotide were verified by dot blot.
Luciferase assay
Luciferase reporter plasmid pRta-luc (pGL2 containing full length (1–3087) Rta promoter) was used to detect the effect of SUMO-interacting domain of LANA on viral gene expression. The luciferase reporter assays were performed as described previously [44]. TK promoter driven Renilla luciferase was used as control to normalize the transfection efficiency.
Extraction and quantitation of KSHV episome DNA
Total DNA was extracted by lysing buffer (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 mM EDTA, 1% SDS) followed by proteinase K digestion. Relative numbers of KSHV episomal copies were calculated by quantitative PCR (qPCR) amplification of the terminal repeats (TR) (primers see supplementary Table S2) as previously described [65]. For extracellular viral DNA, the viral particles were obtained by following the protocol for the virion purification. Bac36 DNA was used to the standards control.
KSHV virion purification
The equal input amount of PEL cells were subjected to induction for KSHV reactivation. After induction, the supernatant of culture medium was collected and filtered through 0.45 µm filter, and viral particles were spun down at 25,000 rpm for 2 h, at 4°C. The concentrated virus was collected and used for viral DNA quantitation.
Supporting Information
Zdroje
1. SoulierJ, GrolletL, OksenhendlerE, CacoubP, Cazals-HatemD, et al. (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86: 1276–1280.
2. ChangY, CesarmanE, PessinMS, LeeF, CulpepperJ, et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865–1869.
3. RussoJJ, BohenzkyRA, ChienMC, ChenJ, YanM, et al. (1996) Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 93: 14862–14867.
4. CaiQ, VermaSC, LuJ, RobertsonES (2010) Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res 78: 87–142.
5. MesriEA, CesarmanE, BoshoffC (2010) Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 10: 707–719.
6. VermaSC, LanK, RobertsonE (2007) Structure and function of latency-associated nuclear antigen. Curr Top Microbiol Immunol 312: 101–136.
7. LukacDM, RenneR, KirshnerJR, GanemD (1998) Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology 252: 304–312.
8. NakamuraH, LuM, GwackY, SouvlisJ, ZeichnerSL, et al. (2003) Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. J Virol 77: 4205–4220.
9. SunR, LinSF, GradovilleL, YuanY, ZhuF, et al. (1998) A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A 95: 10866–10871.
10. XuY, AuCoinDP, HueteAR, CeiSA, HansonLJ, et al. (2005) A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication. J Virol 79: 3479–3487.
11. HassmanLM, EllisonTJ, KedesDH (2011) KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest 121: 752–768.
12. McAllisterSC, MosesAV (2007) Endothelial cell- and lymphocyte-based in vitro systems for understanding KSHV biology. Curr Top Microbiol Immunol 312: 211–244.
13. GanemD (2006) KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 1: 273–296.
14. HockelM, SchlengerK, HockelS, AralB, SchafferU, et al. (1998) Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 79: 365–369.
15. StadlerP, BeckerA, FeldmannHJ, HansgenG, DunstJ, et al. (1999) Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 44: 749–754.
16. TalksKL, TurleyH, GatterKC, MaxwellPH, PughCW, et al. (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157: 411–421.
17. ThomlinsonRH, GrayLH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9: 539–549.
18. CaiQ, LanK, VermaSC, SiH, LinD, et al. (2006) Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions. J Virol 80: 7965–7975.
19. DavisDA, RinderknechtAS, ZoeteweijJP, AokiY, Read-ConnoleEL, et al. (2001) Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood 97: 3244–3250.
20. CaiQ, MurakamiM, SiH, RobertsonES (2007) A potential alpha-helix motif in the amino terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear accumulation of HIF-1alpha in normoxia. J Virol 81: 10413–10423.
21. CarrollPA, KenersonHL, YeungRS, LagunoffM (2006) Latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells activates hypoxia-induced factors. J Virol 80: 10802–10812.
22. CaiQ, VermaSC, KumarP, MaM, RobertsonES (2010) Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. PLoS One 5: e9720.
23. Carbia-NagashimaA, GerezJ, Perez-CastroC, Paez-PeredaM, SilbersteinS, et al. (2007) RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 131: 309–323.
24. ChengJ, KangX, ZhangS, YehET (2007) SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 131: 584–595.
25. van HagenM, OvermeerRM, AbolvardiSS, VertegaalAC (2010) RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2alpha. Nucleic Acids Res 38: 1922–1931.
26. SeelerJS, DejeanA (2003) Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol 4: 690–699.
27. RodriguezMS, DargemontC, HayRT (2001) SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem 276: 12654–12659.
28. SramkoM, MarkusJ, KabatJ, WolffL, BiesJ (2006) Stress-induced inactivation of the c-Myb transcription factor through conjugation of SUMO-2/3 proteins. J Biol Chem 281: 40065–40075.
29. SaitohH, HincheyJ (2000) Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 275: 6252–6258.
30. GuoD, LiM, ZhangY, YangP, EckenrodeS, et al. (2004) A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet 36: 837–841.
31. MintyA, DumontX, KaghadM, CaputD (2000) Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem 275: 36316–36323.
32. SongJ, DurrinLK, WilkinsonTA, KrontirisTG, ChenY (2004) Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci U S A 101: 14373–14378.
33. HannichJT, LewisA, KroetzMB, LiSJ, HeideH, et al. (2005) Defining the SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae. J Biol Chem 280: 4102–4110.
34. LiZ, WangD, NaX, SchoenSR, MessingEM, et al. (2003) The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. Embo J 22: 1857–1867.
35. HeF, LiL, KimD, WenB, DengX, et al. (2007) Adenovirus-mediated expression of a dominant negative Ku70 fragment radiosensitizes human tumor cells under aerobic and hypoxic conditions. Cancer Res 67: 634–642.
36. KoumenisC, AlarconR, HammondE, SutphinP, HoffmanW, et al. (2001) Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 21: 1297–1310.
37. FreedmanSJ, SunZY, PoyF, KungAL, LivingstonDM, et al. (2002) Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A 99: 5367–5372.
38. GirdwoodD, BumpassD, VaughanOA, ThainA, AndersonLA, et al. (2003) P300 transcriptional repression is mediated by SUMO modification. Mol Cell 11: 1043–1054.
39. KuoHY, ChangCC, JengJC, HuHM, LinDY, et al. (2005) SUMO modification negatively modulates the transcriptional activity of CREB-binding protein via the recruitment of Daxx. Proc Natl Acad Sci U S A 102: 16973–16978.
40. PungaliyaP, KulkarniD, ParkHJ, MarshallH, ZhengH, et al. (2007) TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins. J Proteome Res 6: 3918–3923.
41. LiX, LinHH, ChenH, XuX, ShihHM, et al. (2010) SUMOylation of the transcriptional co-repressor KAP1 is regulated by the serine and threonine phosphatase PP1. Sci Signal 3: ra32.
42. GarberAC, ShuMA, HuJ, RenneR (2001) DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Virol 75: 7882–7892.
43. MillerG, HestonL, GroganE, GradovilleL, RigsbyM, et al. (1997) Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J Virol 71: 314–324.
44. CaiQL, KnightJS, VermaSC, ZaldP, RobertsonES (2006) EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog 2: e116.
45. GillG (2005) Something about SUMO inhibits transcription. Curr Opin Genet Dev 15: 536–541.
46. HayRT (2005) SUMO: a history of modification. Mol Cell 18: 1–12.
47. HofmannH, FlossS, StammingerT (2000) Covalent modification of the transactivator protein IE2-p86 of human cytomegalovirus by conjugation to the ubiquitin-homologous proteins SUMO-1 and hSMT3b. J Virol 74: 2510–2524.
48. WuYC, RoarkAA, BianXL, WilsonVG (2008) Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs). Virology 378: 329–338.
49. AdamsonAL, KenneyS (2001) Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol 75: 2388–2399.
50. ChangPC, IzumiyaY, WuCY, FitzgeraldLD, CampbellM, et al. (2010) Kaposi's sarcoma-associated herpesvirus (KSHV) encodes a SUMO E3 ligase that is SIM-dependent and SUMO-2/3-specific. J Biol Chem 285: 5266–5273.
51. IzumiyaY, EllisonTJ, YehET, JungJU, LuciwPA, et al. (2005) Kaposi's sarcoma-associated herpesvirus K-bZIP represses gene transcription via SUMO modification. J Virol 79: 9912–9925.
52. YangSH, GalanisA, WittyJ, SharrocksAD (2006) An extended consensus motif enhances the specificity of substrate modification by SUMO. Embo J 25: 5083–5093.
53. CampbellM, IzumiyaY (2012) Post-Translational Modifications of Kaposi's Sarcoma-Associated Herpesvirus Regulatory Proteins - SUMO and KSHV. Front Microbiol 3: 31.
54. FriedmanJR, FredericksWJ, JensenDE, SpeicherDW, HuangXP, et al. (1996) KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev 10: 2067–2078.
55. Le DouarinB, NielsenAL, GarnierJM, IchinoseH, JeanmouginF, et al. (1996) A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. Embo J 15: 6701–6715.
56. UnderhillC, QutobMS, YeeSP, TorchiaJ (2000) A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1. J Biol Chem 275: 40463–40470.
57. SripathySP, StevensJ, SchultzDC (2006) The KAP1 corepressor functions to coordinate the assembly of de novo HP1-demarcated microenvironments of heterochromatin required for KRAB zinc finger protein-mediated transcriptional repression. Mol Cell Biol 26: 8623–8638.
58. IvanovAV, PengH, YurchenkoV, YapKL, NegorevDG, et al. (2007) PHD domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing. Mol Cell 28: 823–837.
59. LiX, LeeYK, JengJC, YenY, SchultzDC, et al. (2007) Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression. J Biol Chem 282: 36177–36189.
60. ZivY, BielopolskiD, GalantyY, LukasC, TayaY, et al. (2006) Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway. Nat Cell Biol 8: 870–876.
61. ZhangY, IratniR, Erdjument-BromageH, TempstP, ReinbergD (1997) Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. Cell 89: 357–364.
62. ChangPC, FitzgeraldLD, Van GeelenA, IzumiyaY, EllisonTJ, et al. (2009) Kruppel-associated box domain-associated protein-1 as a latency regulator for Kaposi's sarcoma-associated herpesvirus and its modulation by the viral protein kinase. Cancer Res 69: 5681–5689.
63. WeiF, ZapraznaK, WangJ, AtchisonML (2009) PU.1 can recruit BCL6 to DNA to repress gene expression in germinal center B cells. Mol Cell Biol 29: 4612–4622.
64. BaiY, SrinivasanL, PerkinsL, AtchisonML (2005) Protein acetylation regulates both PU.1 transactivation and Ig kappa 3′ enhancer activity. J Immunol 175: 5160–5169.
65. SiH, VermaSC, LampsonMA, CaiQ, RobertsonES (2008) Kaposi's sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic apparatus protein to regulate genome maintenance and segregation. J Virol 82: 6734–6746.
Štítky
Hygiena a epidemiologie Infekční lékařství LaboratořČlánek vyšel v časopise
PLOS Pathogens
2013 Číslo 11
- Perorální antivirotika jako vysoce efektivní nástroj prevence hospitalizací kvůli COVID-19 − otázky a odpovědi pro praxi
- Stillova choroba: vzácné a závažné systémové onemocnění
- Diagnostický algoritmus při podezření na syndrom periodické horečky
- Jak souvisí postcovidový syndrom s poškozením mozku?
- Diagnostika virových hepatitid v kostce – zorientujte se (nejen) v sérologii
Nejčtenější v tomto čísle
- Baculoviruses: Sophisticated Pathogens of Insects
- Identification of the Adenovirus E4orf4 Protein Binding Site on the B55α and Cdc55 Regulatory Subunits of PP2A: Implications for PP2A Function, Tumor Cell Killing and Viral Replication
- Turning Defense into Offense: Defensin Mimetics as Novel Antibiotics Targeting Lipid II
- A Unique SUMO-2-Interacting Motif within LANA Is Essential for KSHV Latency